Therapeutic options for hormone-refractory prostate cancer

被引：0
作者：
Miller K. [1 ,6 ]
Börgermann C. [2 ]
Thüroff J. [3 ]
Albers P. [4 ]
Wirth M. [5 ]
机构：
[1] Urologische Klinik, Charité, Universitätsmedizin, Berlin
[2] Klinik und Poliklinik für Urologie, Universitätsklinikum, Essen
[3] Urologische Klinik, Johannes-Gutenberg-Universität, Mainz
[4] Urologische Klinik, Universität, Bonn
[5] Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Technische Universität, Dresden
[6] Urologische Klinik, Charité, Universitätsmedizin, 12200 Berlin
来源：
Der Urologe | 2006年 / 45卷 / 5期
关键词：
Docetaxel; Hormone-refractory prostate cancer; Taxanes; Zoledronic acid;
D O I：
10.1007/s00120-006-1048-0
中图分类号：
学科分类号：
摘要：
For a long time, hormone-refractory prostate cancer was regarded as a chemoresistant tumor. The introduction of taxanes has prompted a change in this opinion. For the first time treatment with 75 mg/m 2 docetaxel every 3 weeks has evidenced a survival benefit in a phase III trial (median survival of 18.9 months versus 16.5 months with mitoxantrone). Further advantages were improved pain reduction and quality of life. Neutropenia was foremost among the side effects. Docetaxel is currently the standard treatment for hormone-refractory prostate cancer. The morbidity of metastatic hormone-refractory prostate cancer is influenced by bone metastases. Pain is a prominent feature. Skeletal complications are frequent. Therapy with 4 mg zoledronic acid reduced skeletal complications significantly in comparison to placebo. The most pronounced effect is the reduction of pathological fractures. Side effects include flu-like symptoms, muscle pain, and edemas. Zoledronic acid also belongs to the standard treatment of hormone-refractory prostate cancer with bone metastases. © Springer Medizin Verlag 2006.
引用
收藏
页码：580 / 585
页数：5
相关论文
共 21 条
  • [11] Osborne C.K., Blumenstein B.A., Crawford E.D., Et al., Phase II study of platinum and mitoxantrone in metastatic prostate cancer: A Southwest Oncology Group Study, Eur J Cancer, 28, pp. 477-478, (1992)
  • [12] Otto T., Rembrink K., Goepel M., Et al., Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study, Urologe A, 35, pp. 142-145, (1996)
  • [13] Oudard S., Banu E., Beuzeboc P., Et al., Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer, J Clin Oncol, 23, pp. 3343-3351, (2005)
  • [14] Petrylak D.P., Docetaxel (Taxotere) in hormone-refractory prostate cancer, Semin Oncol, 27, pp. 24-29, (2000)
  • [15] Petrylak D.P., Tangen C.M., Hussain M.H., Et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, pp. 1513-1520, (2004)
  • [16] Picus J., Schultz M., Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results, Semin Oncol, 26, pp. 14-18, (1999)
  • [17] Ryan C.J., Small E.J., Role of secondary hormonal therapy in the management of recurrent prostate cancer, Urology, 62, 1 SUPPL., pp. 87-94, (2003)
  • [18] Saad F., Gleason D.M., Murray R., Et al., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, pp. 1458-1468, (2002)
  • [19] Scher H.I., Steineck G., Kelly W.K., Hormone-refractory (D3) prostate cancer: Refining the concept, Urology, 46, pp. 142-148, (1995)
  • [20] Tannock I.F., Osoba D., Stockler M.R., Et al., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points, J Clin Oncol, 14, pp. 1756-1764, (1996)
123